Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pentafuside (Trimeris).

N Press1, B Hedberg, B Conway

  • 1Department of Medicine, Viridae Clinical Sciences, University of British Columbia, 1134 Burrard Street, Vancouver, BC V6Z 1Y8, Canada.

Idrugs : the Investigational Drugs Journal
|August 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.

Drugs of today (Barcelona, Spain : 1998)·2018
Same author

End-stage renal disease and survival in people with diabetes: a national database linkage study.

QJM : monthly journal of the Association of Physicians·2014
Same author

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.

HIV medicine·2013
Same author

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality.

HIV medicine·2012
Same author

Heterosexual transmission of human immunodeficiency virus infection - Strategies for prevention.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Is there anything left to learn? A report on the Fifth International Workshop on HIV Drug Resistance.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Pentafuside (T-20) is a peptide drug candidate that prevents HIV infection by blocking viral membrane fusion. Clinical trials are evaluating its safety and efficacy in combination with other antiretroviral therapies.

Area of Science:

  • Virology
  • Drug Development
  • Immunology

Background:

  • Pentafuside (T-20) is a peptide compound targeting HIV infection.
  • It is a 36 amino acid peptide derived from the HIV-1 gp41 transmembrane protein.
  • Pentafuside received US FDA fast track designation in February 1999.

Purpose of the Study:

  • To evaluate the safety, pharmacokinetics, and antiviral activity of pentafuside.
  • To assess pentafuside in combination with efavirenz and protease inhibitors for HIV treatment.
  • To investigate pentafuside's potential in patients failing existing triple combination therapy.

Main Methods:

  • Preclinical studies demonstrated pentafuside's ability to block HIV infection and cell-to-cell fusion.
  • A clinical trial involved a dose-optimization period assessing safety, pharmacokinetics, and antiviral activity.

Related Experiment Videos

  • An extension period evaluated pentafuside in combination with efavirenz and two protease inhibitors.

    • Main Results:

    • Preclinical studies showed pentafuside effectively blocked HIV infection and cell fusion.
    • The dose-optimization period assessed safety, pharmacokinetics, and antiviral activity of ascending doses.
    • The extension period involved combination therapy with efavirenz and protease inhibitors.

    Conclusions:

    • Pentafuside demonstrates potential as an anti-HIV agent by inhibiting viral membrane fusion.
    • Clinical trials are underway to establish its safety and efficacy in combination regimens.
    • Further research is warranted for pentafuside's role in managing treatment-experienced HIV patients.